PHT Corporation Achieves Industry Landmark with 500th ePRO Clinical Trial

PHT outperforms the competition with science, technology and a superior user experience

BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corporation cemented its reputation as the dominant player and constant innovator in the Patient Reported Outcomes (PRO) and Electronic Patient Reported Outcomes (ePRO) industry with the announcement of its 500^th clinical research trial.

“57 percent of profiled companies will increase their PRO team budgets in 2012 and no profiled company will be decreasing its PRO budget next year.”

The ePRO market has accelerated tremendously in the last few years with the finalization of the FDA PRO Guidance and the increased adoption of ePRO solutions by drug developers around the globe. According to new benchmarking data from research firm Cutting Edge Information, “57 percent of profiled companies will increase their PRO team budgets in 2012 and no profiled company will be decreasing its PRO budget next year.”

PHT President and CEO Philip Lee said, “This is a milestone not just for PHT but for the industry. Global demand for our ePRO Systems and world-class delivery and support continues to skyrocket because PHT anticipates and exceeds the needs of sponsors, CROs and regulators. The use of paper-based PRO continues to diminish as PHT demonstrates to regulators, trial sponsors and patients the deficiencies of paper and the clinical and economic benefits of proven ePRO Systems.” Learn more about why Mr. Lee says the pharmaceutical industry should abolish paper diaries: http://bit.ly/zhg9Tm.

PHT continues to lead the industry by developing innovative new technologies, focusing on customer needs and delivering excellent service.

Brad Whitlow, Clinical Project Manager at GREER, said, “We stopped using paper diaries soon after we began our first ePRO trial with PHT. ePRO is the only way to collect excellent quality data that proves drug efficacy quickly, safely and economically. We would not consider using any other ePRO System for our clinical trials.”

PHT is the only company that supports all phases of clinical development including post-market studies. It offers a complete ePRO System that collects patient data via smartphone, tablet, Internet or dedicated handheld device. By leveraging the Internet, PHT can create potentially huge cost savings, particularly in late phase and post-market studies which have large global populations and traditionally have used paper to collect outcome data from patients. Pharmaceutical, biotechnology and life sciences companies of all sizes have leveraged PHT’s ePRO Systems to collect accurate, reliable clinical trial subject data.

Mr. Lee added, “In addition to thanking our customers and partners, I want to acknowledge every member of the PHT team worldwide for this outstanding achievement as we commit ourselves to advancing ePRO for the next 500 clinical trials.”

About PHT Corporation

PHT Corporation is the industry's only dedicated full-service ePRO provider. PHT offers clients a comprehensive solution for acquiring, managing and analyzing data collected directly from patients through all phases of clinical development. More than 115 biopharmaceutical companies in more than 500 trials have used PHT's ePRO System to easily collect high quality, regulatory-compliant clinical trial data. PHT's proven LogPad®, NetPRO™ and versatile SitePad® Systems deliver the voice of the patient, in 97 languages, from homes and sites in 67 countries around the world. Patient experiences captured firsthand by PHT's ePRO System have been used successfully in at least 18 regulatory submissions and 16 approvals to date resulting in 14 PRO-based label claims for sponsors. For more information on PRO and ePRO innovations, review the interactive content and demonstrations at phtcorp.com. Follow PHT on Twitter.

PHT, LogPad, NetPRO, and SitePad are registered trademarks of PHT Corporation. NetPRO and SmartReports are trademarks of PHT Corporation.